---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-047276"
form_type: "8-K"
ticker: "DNA"
cik: "0001830214"
company_name: "Ginkgo Bioworks Holdings, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:10:39.762427+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ginkgo Q3 total rev $89M (+61% YoY) includes $45M deferred release; core $44M (-21%); guides FY $215-235M

## Summary
- Total revenue $89M (+61% YoY) incl. $45M non-cash deferred revenue; core rev $44M (-21%).
- Cell Engineering ex-deferred $30M (-20% YoY); Biosecurity $14M with 28% gross margin.
- Loss from ops $(55)M vs $(286)M; Adj EBITDA $(20)M vs $(84)M.
- FY24 guidance raised: Total rev $215-235M, Cell Eng $165-185M, Biosecurity ≥$50M.
- Appointed Dr. Sri Kosuri to Board; Dr. Belldegrun resigned. Signed deal with Novo Nordisk; Merck milestone $9M.

## SEC filing metadata
- accession: 0001628280-24-047276
- form_type: 8-K
- ticker: DNA
- cik: 0001830214
- company_name: Ginkgo Bioworks Holdings, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1830214/000162828024047276/0001628280-24-047276-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1830214/000162828024047276/dna-20241106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-047276
- JSON: https://secwatch.observer/filing/0001628280-24-047276.json
- Plain text: https://secwatch.observer/filing/0001628280-24-047276.txt

## Key facts
- Executive change
  Dr. Arie Belldegrun resigned as Director at Ginkgo Bioworks Holdings, Inc..
  - Action: resigned
  - Role: Director
  source text: On November 7, 2024, Dr. Arie Belldegrun resigned from his position as a director of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1830214/000162828024047276/0001628280-24-047276-index.htm
- Executive change
  Dr. Sri Kosuri was appointed as Class B Director at Ginkgo Bioworks Holdings, Inc..
  - Action: appointed
  - Role: Class B Director
  source text: On November 6, 2024, the Class B directors of the board of directors (the “Board”) of the Company appointed Dr. Sri Kosuri to the Board as a Class B director.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1830214/000162828024047276/0001628280-24-047276-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.